MSN’s Formulation R&D division focuses on developing various dosage forms that meet stringent international quality standards. The facility plays a pivotal role in addressing therapy gaps and delivering affordable access to medicines across geographies.

Speciality

Development of various oral formulations including tablets, capsules, bi-layered tablets, sublingual, dispersible, sustained-release, and delayed-release forms

Special expertise in lifecycle extension strategies, including novel polymorphs and salt forms

Known for introducing innovative therapies in India not launched by innovators, bridging access gaps in Cardio, PAH, Oncology, Psychiatry, and more

Infrastructure

Integrated R&D Center

One of Asia’s largest integrated formulation R&D campuses, designed for end-to-end development. Supports clinical batches, technology transfer, and scale-up capabilities.

Therapy-Aligned R&D Divisions

Formulation R&D is divided into focused teams like Cardiology, Diabetology, Pulmonology, Oncology, and Gastroenterology. This therapy-wise structure allows deep focus and tailored innovation.

High-End Analytical Instruments

Includes dissolution testers, particle size analyzers, HPLCs, UPLCs, and equipment for polymorph screening. Supports data-driven formulation development and ensures regulatory robustness.

Stability Chambers

ICH-compliant accelerated and long-term stability chambers. Ensures consistent product performance across shelf-life and geographies.

Dosage Forms

Capabilities

Formulation Development
Expertise in multiple oral dosage formats with customized release profiles. Teams focus on designing bioequivalent, patient-friendly, and scalable products for regulated markets.
Technology Transfer
Smooth transfer of lab-scale formulations to manufacturing with full documentation, validation, and QA oversight. Ensures minimal deviation and faster commercialization.
Bioequivalence and Dossier Support
Strong track record in BE studies, clinical support, and compiling CTDs for US, EU, and ROW submissions. Accelerates time-to-market and regulatory approval.
Patent Strategy & IP Innovation
Focused on developing non-infringing formulations using techniques like amorphous / crystalline conversion, particle size engineering, and salt selection. Ensures extended product lifecycle and market exclusivity.

Reports

The Sustainability Report of the MSN group of Companies reflects the group’s commitment to incorporate environmental, social, and governance (ESG) consideration into its operations and decision making processes. Download the sustainability report 2023 & 2024

Sustainability Report

Reach Out to Us for More Info

Know More